drugset / Trial / NCT05665114
Natural Killer(NK) Cell Therapy in r/r AML
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, Phase I study of QN-030a (allogeneic NK cell therapy) in relapse/refractory Acute Myeloid Leukemia (AML). This clinical study is to evaluate the safety, tolerability and preliminary efficacy of QN-030a in patients with r/r AML, where a "3+3" enrollment schema will be utilized at dose escalation stage. Up to 18 patients will be enrolled.
Timeline
- Start
- 2022-12-24
- Primary completion
- 2023-12-24
- Completion
- 2025-12-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QN-030a | Cell therapy | — | — |
| Background | Cyclophosphamid | Unknown | — | — |
| Background | Cytarabine | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | — |